[HTML][HTML] TG02, an oral CDK9-inhibitor, in combination with carfilzomib demonstrated objective responses in carfilzomib refractory multiple myeloma patients
CC Hofmeister, JG Berdeja, DH Vesole… - Blood, 2015 - Elsevier
Introduction: TG02 is an orally-bioavailable, multikinase inhibitor where the primary
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …
TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients
CC Hofmeister, JG Berdeja, DH Vesole… - 2015 - ashpublications.org
Introduction: TG02 is an orally-bioavailable, multikinase inhibitor where the primary
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …